

Original article

Evaluating the accuracy of different respiratory specimens in the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV infections

Yang Yang*, Minghui Yang*, Chenguang Shen*, Fuxiang Wang*, Jing Yuan*, Jinxiu Li, Mingxia Zhang, Zhaoqin Wang, Li Xing, Jinli Wei, Ling Peng, Gary Wong, Haixia Zheng, Weibo Wu, Mingfeng Liao, Kai Feng, Jianming Li, Qianting Yang, Juanjuan Zhao, Zheng Zhang†, Lei Liu†, Yingxia Liu†

Shenzhen Key Laboratory of Pathogen and Immunity, National Clinical Research Center for Infectious Disease, State Key Discipline of Infectious Disease, Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, Shenzhen, China (Dr. Y Yang MD, Dr M Yang PhD, Dr C Shen PhD, Prof F Wang MD, Prof J Yuan MD, Pro J Li MD, Pro M Zhang MM, Pro Z Wang MD, Ms L Xing MM, Ms J Wei MM, Ms L Peng MM, Ms H Zheng MM, Mr W Wu MM, Dr M Liao MD, Mr K Feng MM, Pro J Li MM, Dr Q Yang MD, Dr J Zhao MD, Pro Z Zhang PhD, Pro L Liu MD, Pro Y Liu MD)

Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai, China (Pro G Wong PhD)

*Contributed equally.

†Contributed equally.

Correspondence to: Drs. Liu and Dr Zhang; Shenzhen Third People's Hospital, Second Hospital Affiliated to Southern University of Science and Technology, No.29, Bulan Road, Longgang district, Shenzhen 518112, China; yingxialiu@hotmail.com, liulei3322@aliyun.com and zhangzheng1975@aliyun.com.

1 **ABSTRACT:**

2 **Background** The outbreak of novel coronavirus pneumonia (NCP) caused by
3 2019-nCoV spread rapidly, and elucidating the diagnostic accuracy of different
4 respiratory specimens is crucial for the control and treatment of this disease.

5 **Methods** Respiratory samples including nasal swabs, throat swabs, sputum and
6 bronchoalveolar lavage fluid (BALF) were collected from Guangdong CDC
7 confirmed NCP patients, and viral RNAs were detected using a CFDA approved
8 detection kit. Results were analyzed in combination with sample collection date and
9 clinical information.

10 **Findings** Except for BALF, the sputum possessed the highest positive rate
11 (74.4%~88.9%), followed by nasal swabs (53.6%~73.3%) for both severe and mild
12 cases during the first 14 days after illness onset (d.a.o). For samples collected ≥ 15
13 d.a.o, sputum and nasal swabs still possessed a high positive rate ranging from
14 42.9%~61.1%. The positive rate of throat swabs collected ≥ 8 d.a.o was low,
15 especially in samples from mild cases. Viral RNAs could be detected in all the lower
16 respiratory tract of severe cases, but not the mild cases. CT scan of cases 02, 07 and
17 13 showed typical viral pneumonia with ground-glass opacity, while no viral RNAs
18 were detected in first three or all the upper respiratory samples.

19 **Interpretation** Sputum is most accurate for laboratory diagnosis of NCP, followed
20 by nasal swabs. Detection of viral RNAs in BLAF is necessary for diagnosis and
21 monitoring of viruses in severe cases. CT scan could serve as an important make up
22 for the diagnosis of NCP.

23 **Funding** National Science and Technology Major Project, Sanming Project of
24 Medicine and China Postdoctoral Science Foundation.

25

26 INTRODUCTION

27 The outbreak of NCP caused by the novel coronavirus, designated as 2019-nCoV,
28 started in Wuhan, China, at the end of 2019 ¹. As of Feb. 5, 2020, at least 24324 cases
29 and 490 deaths have been identified across China and other countries ²⁻⁵. On Jan.
30 30, 2020, WHO has declared that the outbreak of 2019-nCoV constitutes a Public
31 Health Emergency of International Concern (PHEIC) and issued this advice as
32 temporary recommendations under the International Health Regulations (IHR).

33 Clinical features varied in different cases, and some patients showed
34 asymptomatic infection ^{2,6-8}. Recent studies have confirmed the human to human
35 transmission of 2019-nCoV ^{2,3,6,8}. More importantly, asymptomatic cases could
36 transmit virus to other contacts, which makes it more difficult to control the spread of
37 the virus ². Rapid and accurate detection of 2019-nCoV is in urgent need due to the
38 rapid spread and increasing number of NCP patients ⁶. Studies have shown that
39 pneumonia is the common complication of 2019-nCoV infection ^{6,7}, which suggests
40 that it mainly infects the lower respiratory tract. Until recently, the diagnosis of the
41 cases in the published studies was mostly from the lower respiratory tract specimens ⁷.
42 However, collection of the lower respiratory samples (usually BALF) requires both a
43 suction device and a skilled operator, also painful for the patients. So, BALF samples
44 are not feasible for the routine laboratory diagnosis and monitoring of the 2019-nCoV.
45 Instead, collection of a nasal swab, throat swab and sputum is rapid, simple and safe.

46 Accordingly, elucidating the diagnosis accuracy of different sample types is
47 crucial for the laboratory diagnosis and monitoring the viral shedding of 2019-nCoV.
48 Moreover, no data on the difference of viral shedding between the upper and lower
49 respiratory tract specimens is currently available. In this study, we aim to investigate
50 the diagnostic accuracy of the upper respiratory samples, and compare the viral

51 distribution and shedding between the mild and severe cases. We believe our results
52 would help the laboratory staff and physicians in the diagnosis and treatments of
53 patients with 2019-nCoV.

54

55

56 **METHODS**

57 **Patients and samples**

58 213 Guangdong CDC (Center for Disease Control and Prevention) confirmed
59 2019-nCoV infected patients who were hospitalized in Shenzhen Third People's
60 hospital between Jan 11 and Feb. 03, 2020 were included. A total of 866 samples from
61 respiratory tracts of the patients including nasal swabs, throat swabs, sputum and
62 BALF were collected upon admission and various time-points thereafter. Sample
63 collection dates were divided into 0~7, 8~14 and ≥ 15 d.a.o groups, and patients were
64 divided into severe and mild cases according to the guidelines of 2019-nCoV
65 infection from the National Health Commission of the People's Republic of China.
66 The study was approved by the Ethics Committees from Shenzhen Third People's
67 Hospital (SZTHEC2016001).

68 **Quantitative reverse transcription polymerase chain reaction**

69 Viral RNAs were extracted from the samples using the QIAamp RNA Viral Kit
70 (Qiagen, Heiden, Germany), and quantitative reverse transcription polymerase chain
71 reaction (qRT-PCR) was performed using a China Food and Drug Administration
72 (CFDA) approved commercial kit specific for 2019-nCoV detection (GeneoDX Co.,
73 Ltd., Shanghai, China). The specimens were considered positive if the Ct value was \leq
74 37.0, and negative if the results were undetermined. Specimens with a Ct higher than
75 37 were repeated. The specimen was considered positive if the repeat results were the

76 same as the initial result and between 37 and 40. If the repeat Ct was undetectable, the
77 specimen was considered negative.

78 **Quantification of hypoxia and lung injury**

79 Quantification of hypoxia and lung injury was carried out as previously reported^{9,10}.
80 In brief, the partial pressure of oxygen (PaO₂) in arterial blood taken from the patients
81 at various time-points after hospitalization was measured by the ABL90 blood gas
82 analyzer (Radiometer). The fraction of inspired oxygen (FiO₂) is calculated by the
83 following formula: $FiO_2 = (21 + \text{oxygen flow (in units of l/min)} \times 4) / 100$. The
84 PaO₂/FiO₂ ratio (in units of mmHg) is calculated by dividing the PaO₂ value with the
85 FiO₂ value.

86 **Statistics analyses**

87 The unpaired, two-tailed *t*-test was used to determine whether differences in the Ct
88 values were statistically significant. The Fisher exact test analysis was used to analyze
89 positive rate. A *p*-value lower than 0.05 was considered statistically significant.
90 Statistical analyses were performed using GraphPad Prism.

91 **Role of the funding sources**

92 The funders of the study had no role in study design, data collection, data analysis,
93 data interpretation or writing of the report. The corresponding author had full access
94 to all the data in the study and had final responsibility for the decision to submit for
95 publication.

96

97

98 **RESULTS**

99 **Patients and sample profile**

100 Altogether, 866 respiratory specimens from 213 patients were collected, including

101 205 throat swabs, 490 nasal swabs, 142 sputum and 29 BALF. Of these patients, 37
102 were in severe or critical conditions, and the rest were mild cases (Table 1). The
103 median age of severe cases is 65, and ranged from 34 to 81. Most of the patients
104 belonged to the 45-64 (43.2%) and ≥ 65 (51.4) years of age groups (Table 1). For the
105 mild cases, the median age is 47 with a range of 2 to 86. Unlike the severe cases, most
106 of the mild cases belonged to the 15-44 (42.05%) and 45-64 (42.05%) years of age
107 groups. The male ratio (62.2%) seems like higher than female in severe cases, but
108 there is no statistical difference. Moreover, the sex ratio is similar in both groups of
109 severe and mild cases. The median d.a.o of collection of the first specimen were 7 and
110 4 for the severe and mild cases, respectively (Table 1). The median number of
111 specimens collected from each patient was 3 (range 1-23).

112

113 **Detection of 2019-nCoV in different respiratory sites NCP cases**

114 The collected different types of specimens from 2019-nCoV confirmed cases were
115 divided into three groups based on the collection time, including the 0~7 d.a.o, 8~14
116 d.a.o and ≥ 15 d.a.o groups. The qPCR assay was performed for each specimen and
117 the results were shown in table 2. For the 0~7 d.a.o group, the sputum sample showed
118 the highest positive rate in both severe (88.9%) and mild (82.2%) cases, follow by
119 nasal swabs (73.3%, 72.1%) and then the throat swabs (60.0%, 61.3%). In the mild
120 cases, the positive rates from nasal swabs and sputum were similar. BLAF collected
121 during 8~14 d.a.o in the severe cases showed 100% positive, while negative in the
122 BALF of three mild cases. The sputum collected during 8~14 d.a.o also show the
123 highest positive rate among the upper respiratory samples in both severe and mild
124 cases, much higher than the nasal and throat swabs. Of note, the positive rate of throat
125 swabs is only 50% in severe and 29.6% in mild cases. BALF, sputum and nasal swabs

126 collected from severe cases ≥ 15 d.a.o showed similar positive rate. In mild cases, the
127 positive rates of sputum and nasal swabs were similar, much higher than the throat
128 swabs. In addition, the Ct values were significantly lower in sputum from severe
129 cases.

130

131 **Profiles of viral shedding in severe and mild NCP cases**

132 Serial samples from both upper (including throat swabs, nasal swabs and sputum,
133 marked in red) and lower (BALF, marked in blue) respiratory tract from 13 NCP cases
134 were collected and analyzed. The patients were grouped into severe (N=10, marked in
135 red) and mild (N=3, marked in blue) cases and the detection results were shown in
136 Figure 2. Viral RNAs could be detected in the upper respiratory tract samples
137 collected during 3 and 21 d.a.o, and detected in BLAF at 23 d.a.o with high viral load.
138 In severe cases, viral RNAs were detected in all the BALF samples as early as 6 d.a.o,
139 and upper respiratory samples from 10 (10/11) cases. In case 2, although the Ct value
140 was low in BALF, viral RNAs were not detected in all the upper respiratory samples.
141 Meanwhile, for some severe cases (cases 06 and 07), viral RNAs were not detected in
142 all the upper respiratory samples. As to the 3 mild cases, the viral RNAs was only
143 detected in the upper respiratory samples, not in the BLAF. Moreover, the duration of
144 viral shedding is longer in most of the severe cases.

145

146 **Computed tomography (CT) scan may serve as an important make up for the** 147 **diagnosis of NCP**

148 The epidemiological and clinical features of cases 02, 07 and 13 from whom viral
149 RNA were not detected in the first three or all the upper respiratory samples were
150 analyzed in detail (Table 3 and Fig 2). Case 02 was a female aged 65 with

151 hypertension, and case 07 was a male aged 34 without any underlying diseases. Both
152 them had a travelling history to Wuhan. The CT scan of the two cases showed
153 multiple ground-glass opacities in bilateral lungs. The PiO_2/FiO_2 and Murray score
154 were 188 and 2 for case 02, 306 and 1.5 for case 07, which indicated a lung injury.
155 For the two cases, no viral RNAs were detected in the upper respiratory tract but
156 positive in the BALF. Case 13 was a male 36 without any underlying diseases. Due to
157 the exposure history ⁸, CT scan and viral screen were done. The CT scan of this
158 case also showed typical ground-glass opacity in the lung, suggesting a viral
159 pneumonia (Fig 2). However, no viral RNAs were detected until the fourth upper
160 respiratory samples.

161

162

163 **DISCUSSION**

164 According to our results, apart from the BALF collected during 8~14 d.a.o which
165 possessed the 100% (12/12) positive rate, sputum samples showed the highest positive
166 rate in all stages post 2019-nCoV infection, and followed by nasal swabs. The positive
167 rate of throat swab varied in the severe and mild cases. For the severe cases, the
168 positive rates were similar in samples collected 0~7 and 8~14 d.a.o, while low in
169 samples collected ≥ 15 d.a.o. For the mild cases, it showed the highest positive rate in
170 samples collected 0~7 d.a.o, however, very low positive rate in samples collected
171 8~14 and ≥ 15 d.a.o. The results indicate that sputum may serve as the most sensitive
172 samples for the virus detection, and followed by nasal swabs. However, a recent study
173 found that only a small portion (28%) of NCP cases showed sputum production ⁷. As
174 a result, nasal swabs may be the most widely applicable samples for virus detection.
175 On the contrary, throat swabs were not recommended for the viruses detection,

176 especially the samples collected 8~14 and ≥ 15 d.a.o from mild cases, which may
177 result in a large proportion of false negative results.

178 Laboratory detection of viral RNA in the respiratory samples of suspected
179 individuals is now considered one of the criteria for the diagnosis of NCP, and the
180 samples from upper respiratory tract were regularly used (<http://www.nhc.gov.cn/yzygj/s7653p/202002/3b09b894ac9b4204a79db5b8912d4440.shtml>). However, as shown
181 in our study (Fig 1), viral RNAs could not be detected in the upper respiratory
182 samples from some severe cases (cases 02, 06 and 07), while positive in the BALF.
183 Moreover, in some patients like cases 04 and 13, the viruses were not detected in the
184 first three samples, mostly in the 0~7 d.a.o. The results suggest that the suspected
185 patients especially those with exposure history and clinical symptoms might not be
186 excluded from NCP despite that viral RNA was not detected in the upper respiratory
187 samples. Since human to human transmission of 2019-nCoV have been proved in
188 recent studies ^{2,3,6,8}, we must pay more attention to these people, in case of further
189 spread of the virus. Under such circumstances, CT scan might provide important
190 make up for the diagnosis of NCP patients. For example, although no viral RNAs
191 were detected in the first three or all the upper respiratory samples from cases 02, 07
192 and 13, the CT scans showed typical viral pneumonia linked to NCP ^{7,11,12}, and finally
193 2019-nCoV were identified. Another notification is that, during the antiviral treatment,
194 even though we did not detect the viral RNA in the upper respiratory tract, while it
195 was still positive in the BALF samples of some patients (cases 01, 06 and 07).
196 Therefore, detection of the viral RNA in the BALF might be necessary for the
197 monitoring of viral shedding, especially the patients in severe conditions.

199 Studies have shown that 2019-nCoV could utilize Angiotensin-converting
200 enzyme 2 (ACE2) as the receptor to infect the host as SARS-CoV did ^{11,13}.

201 Interestingly, BALF samples from the severe cases possessed 100% positive rate,
202 while in contrast, no viral RNAs were detected in the three BALF samples from mild
203 cases. Although the sample size was small, it also suggests that the viral distribution is
204 associated with diseases severity. More importantly, why the viruses in some
205 individuals retained in the upper respiratory tract merits further elucidation.

206 Our study also has some limitations. Firstly, all the included cases were
207 CDC-confirmed NCP patients, which may result in bias of sample selection.
208 Meanwhile, studies have shown that 2019-nCoV caused asymptomatic infection in
209 some individuals^{2,7,8}, and information of such patients is missing in our study.
210 Secondly, most of samples were collected after antiviral treatment, which may
211 influence the viral shedding. Third, the number of BALF samples was limited,
212 especially for the mild cases. So, it is necessary to include more BALF samples to
213 draw a more precise conclusion on the differences of viral shedding between the
214 severe and mild cases.

215 In conclusion, sputum is most accurate for laboratory diagnosis of NCP, followed
216 by nasal swabs, while throat swabs was not recommended for the diagnosis. Detection
217 of viral RNAs in BLAF is necessary for the diagnosis and monitoring of viruses in
218 severe cases. In addition, CT scan could serve as an important make up for the
219 diagnosis of NCP. The NCP cases are rapidly increasing, and we hope that this study
220 could provide useful information for the diagnosis and control of the 2019-nCoV
221 infection.

222

223

224 **CONTRIBUTOR**

225 YL, LL, ZZ, YY contributed to the study design. FW, JY, JL, MZ, ZW, LP, WW, JL

226 contributed to the collection of clinical specimens. LX, JW, HZ, KF, QY, ML, JZ
227 contributed to experiments and data collection. YY, MY and CS contributed to the
228 data analysis. YY, MY, CS and WG contributed to the manuscript preparation.

229

230 **ACKNOWLEDGMENTS**

231 This work was supported by the National Science and Technology Major Project
232 (2017ZX10103011, 2017ZX10204401, 2018ZX10711001), Sanming Project of
233 Medicine in Shenzhen (SZSM201412003, SZSM201512005) and China Postdoctoral
234 Science Foundation (2019T120147, 2019M660836).

235

236

237 **DECLARATION OF INTERESTS**

238 We declare no competing interests.

239

240

241 **REFERENCES**

- 242 1. Zhu N, Zhang D, Wang W, et al. A Novel Coronavirus from Patients with
243 Pneumonia in China, 2019. *N Engl J Med* 2020.
- 244 2. Rothe C, Schunk M, Sothmann P, et al. Transmission of 2019-nCoV Infection
245 from an Asymptomatic Contact in Germany. *N Engl J Med* 2020.
- 246 3. Phan LT, Nguyen TV, Luong QC, et al. Importation and Human-to-Human
247 Transmission of a Novel Coronavirus in Vietnam. *N Engl J Med* 2020.
- 248 4. Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus
249 in the United States. *N Engl J Med* 2020.
- 250 5. China NHCotPsRo. Daily briefing on novel coronavirus cases in China. 2020.
251 http://en.nhc.gov.cn/2020-02/05/c_76219.htm (accessed Feb. 05 2020).
- 252 6. Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of
253 Novel Coronavirus-Infected Pneumonia. *N Engl J Med* 2020.
- 254 7. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019

- 255 novel coronavirus in Wuhan, China. *Lancet* 2020.
- 256 8. Chan JF, Yuan S, Kok KH, et al. A familial cluster of pneumonia associated with
257 the 2019 novel coronavirus indicating person-to-person transmission: a study of a
258 family cluster. *Lancet* 2020.
- 259 9. Yang Y, Wong G, Yang L, et al. Comparison between human infections caused by
260 highly and low pathogenic H7N9 avian influenza viruses in Wave Five: Clinical and
261 virological findings. *J Infect* 2019; **78**(3): 241-8.
- 262 10. Bi Y, Tan S, Yang Y, et al. Clinical and immunological characteristics of human
263 infections with H5N6 avian influenza virus. *Clin Infect Dis* 2018.
- 264 11. Zhou P, Yang X-L, Wang X-G, et al. A pneumonia outbreak associated with a new
265 coronavirus of probable bat origin. *Nature* 2020.
- 266 12. Lei J, Li J, Li X, Qi X. CT Imaging of the 2019 Novel Coronavirus (2019-nCoV)
267 Pneumonia. *Radiology* 2020: 200236.
- 268 13. Wu F, Zhao S, Yu B, et al. A new coronavirus associated with human respiratory
269 disease in China. *Nature* 2020.
- 270

271 **Table 1. Baseline characteristics and specimens of NCP cases.**

Characteristic	NCP cases		
	Total (N=213)	Severe (N=37)	Mild (N=176)
Median age (range)	52 (2-86)	65 (34-81)	47 (2-86)
Age subgroup (N, %)	213	37	176
<15 yr	9 (4.2)	0 (0)	9 (5.1)
15-44 yr	76 (35.7)	2 (5.4)	74 (42.05)
45-64 yr	90 (42.3)	16 (43.2)	74 (42.05)
≥65 yr	38 (17.8)	19 (51.4)	19 (10.8)
Male (n, %)	108 (50.7)	23 (62.2)	85 (48.3)
Sample types (N)	866	260	606
Throat swabs	205 (23.7)	93	112
Nasal swabs	490 (56.6)	96	394
Sputum	142 (16.4)	45	97
BALF	29 (3.3)	26	3
Median d.a.o of first specimen collection (range)	5 (1-17)	7 (2-16)	4 (1-17)
Median number of specimens for each patient (range)	3 (1-23)	5 (1-23)	3 (1-12)
0~7 d.a.o	2 (1-7)	2 (1-6)	2 (1-7)
8~14 d.a.o	3 (1-10)	4 (1-10)	2 (1-9)
≥15 d.a.o	3 (1-16)	5.5 (1-16)	2 (1-6)

272 d.a.o: Days after illness onset.

273 NCP: Novel coronavirus pneumonia.

274 yr: Years of age.

275 **Table 2. Detection of 2019-nCoV in respiratory sites of NCP cases.**

Collection date	Sample types	NCP cases		
		Severe	Mild	<i>p values</i>
0~7 d.a.o				
Positive rate (n/N, %)	Throat	12/20 (60.0)	46/75 (61.3)	1.000
	Nasal	11/15 (73.3)	147/204 (72.1)	1.000
	Sputum	8/9 (88.9)	37/45 (82.2)	0.26
	BALF	0/0 (0)	0/0 (0)	NA
Ct values (median; range)*	Throat	28.14 (18.86~35.4)	28.7 (17.19~33.44)	0.721
	Nasal	29 (19.19~36.1)	28.98 (17.58~37)	0.569
	Sputum	25 (20~30.17)	28.5 (18~36)	0.059
	BALF	NA	NA	NA
8~14 d.a.o				
Positive rate (n/N, %)	Throat	18/36 (50.0)	8/27 (29.6)	0.127
	Nasal	34/47 (72.3)	96/179 (53.6)	0.03
	Sputum	15/18 (83.3)	32/43 (74.4)	525
	BALF	12/12 (100)	0/3 (0)	0.002
Ct values (median; range)	Throat	29.6 (25~35)	28.36 (23.99~33.71)	0.115
	Nasal	32.09 (22~36.4)	30 (16.69~37)	0.133
	Sputum	26.5 (22.4~34)	31.32 (22~36)	0.025
	BALF	26.75 (19~34)	NA	
≥15 d.a.o				
Positive rate (n/N, %)	Throat	14/38 (36.8)	1/9 (11.1)	0.236
	Nasal	17/34 (50.0)	6/11 (54.5)	1.000
	Sputum	11/18 (61.1)	3/7 (42.9)	0.656
	BALF	11/14 (78.6)	0/0 (0)	NA
Ct values (median; range)	Throat	33.62 (26~36.25)	NA	NA
	Nasal	33 (25.21~37)	29.32 (23.79~36)	0.6
	Sputum	26.55 (19.78~34.09)	33.79 (25~33.8)	0.049
	BALF	29.8 (26~36)	NA	NA

276 NA: Not available.

277 BALF: Bronchoalveolar lavage fluid.

278 d.a.o: Days after illness onset.

279 NCP: Novel coronavirus pneumonia.

280 * Lower cycle threshold (Ct) values indicate higher viral loads


281 **Table 3. Epidemiological and clinical characteristics of cases 2, 7 and 13.**

Case No.	Sex	Age	Initial symptoms	Underling diseases	Possible exposure	Indexes of lung injury	
						PiO ₂ /FiO ₂	Murray score
Case 02	Female	65	Fever, cough, myalgia, chill and diarrhea	Hypertension	Travelled to Wuhan	188	1.75
Case 07	Male	34	Fever, myalgia and diarrhea	No	Lived in Wuhan	306	1.5
Case 13	Male	36	Cough and diarrhea	No	Travelled to Wuhan with case 02	438	0.25

282

283 **FIGURE LEGENDS**

284



285

286 **Figure 1. Serial detection of viral RNAs in the upper and lower respiratory tract**


287 **of 13 NCP cases.** Number of cases with severe condition were marked in red, and

288 mild condition in blue. The detection results of samples from upper respiratory tract

289 were in red, and lower respiratory tract in blue. Lower cycle threshold (Ct) values

290 indicate higher viral loads.

291



292

293 **Figure 2.** Computed tomography (CT) scan of the cases 02, 07 and 13.

294